
Almirall welcomes UCB head into Board of directors
pharmafile | October 29, 2012 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing |Â Â Almirall, Gerhard MayrÂ
Almirall has approved the appointment of Gerhard Mayr as a new independent member to its Board of directors.
He is currently president of the Board of directors of UCB and a member of the Board at Lonza. The Austrian chemical engineer has extensive international experience in the healthcare sector and has managed several business models in pharma.
Mayr’s career spans over 40 years in a variety of companies within the pharmaceutical sector. His strategic vision, outstanding innovative capacity, leadership in stock market environments and extensive international experience advocate his appointment as Board member, Almirall add.
Headquartered in Barcelona, Almirall researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people’s health and wellbeing with a focus on respiratory, gastrointestinal, dermatology and pain.
Related Content

Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment
Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk …

Almirall gains EC approval of Ebglyss for moderate-to-severe atopic dermatitis
Almirall has announced that the European Commission (EC) has approved Ebglyss (lebrikizumab) for the treatment …
Almirall: The New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD) publish Ph3 data evaluating lebrikizumab efficacy and safety in moderate-to-severe atopic dermatitis
BARCELONA, Spain. March 31, 2023 – Almirall, S.A. (ALM), a global biopharmaceutical company focused on …






